SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment
The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/9/3377 |
| _version_ | 1797568289760608256 |
|---|---|
| author | Marcella Prete Elvira Favoino Giacomo Catacchio Vito Racanelli Federico Perosa |
| author_facet | Marcella Prete Elvira Favoino Giacomo Catacchio Vito Racanelli Federico Perosa |
| author_sort | Marcella Prete |
| collection | DOAJ |
| description | The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed. |
| first_indexed | 2024-03-10T19:55:22Z |
| format | Article |
| id | doaj.art-4a4bd7a467b84404bb2bd51f471b1bf7 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T19:55:22Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-4a4bd7a467b84404bb2bd51f471b1bf72023-11-20T00:00:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-05-01219337710.3390/ijms21093377SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological TreatmentMarcella Prete0Elvira Favoino1Giacomo Catacchio2Vito Racanelli3Federico Perosa4Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, ItalySystemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, ItalySystemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, ItalyUnit of Internal Medicine, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, ItalySystemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, ItalyThe current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.https://www.mdpi.com/1422-0067/21/9/3377anti-cytokine antibodieshuman immunoglobulin for intravenous useCOVID-19SARS-CoV-2inflammationacute respiratory syndrome |
| spellingShingle | Marcella Prete Elvira Favoino Giacomo Catacchio Vito Racanelli Federico Perosa SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment International Journal of Molecular Sciences anti-cytokine antibodies human immunoglobulin for intravenous use COVID-19 SARS-CoV-2 inflammation acute respiratory syndrome |
| title | SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment |
| title_full | SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment |
| title_fullStr | SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment |
| title_full_unstemmed | SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment |
| title_short | SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment |
| title_sort | sars cov 2 inflammatory syndrome clinical features and rationale for immunological treatment |
| topic | anti-cytokine antibodies human immunoglobulin for intravenous use COVID-19 SARS-CoV-2 inflammation acute respiratory syndrome |
| url | https://www.mdpi.com/1422-0067/21/9/3377 |
| work_keys_str_mv | AT marcellaprete sarscov2inflammatorysyndromeclinicalfeaturesandrationaleforimmunologicaltreatment AT elvirafavoino sarscov2inflammatorysyndromeclinicalfeaturesandrationaleforimmunologicaltreatment AT giacomocatacchio sarscov2inflammatorysyndromeclinicalfeaturesandrationaleforimmunologicaltreatment AT vitoracanelli sarscov2inflammatorysyndromeclinicalfeaturesandrationaleforimmunologicaltreatment AT federicoperosa sarscov2inflammatorysyndromeclinicalfeaturesandrationaleforimmunologicaltreatment |